Literature DB >> 8677985

Frequency and clinical profile of precore and surface hepatitis B mutants in Asian-Indian patients with chronic liver disease.

R C Guptan1, V Thakur, S K Sarin, K Banerjee, P Khandekar.   

Abstract

BACKGROUND: Infection due to hepatitis B virus (HBV) could be due to wild or mutant (precore or surface) viruses. The prevalence and clinical profile of different viral forms in patients with chronic liver disease has not been established.
METHODS: One hundred and twenty patients with histologically proven HBV-related chronic liver disease were studied. Patients with dual infection with HCV/HDV/HIV, past history of interferon therapy, or autoimmune hepatitis were excluded. Eighteen (15.5%) patients had the precore mutation (HBsAg +ve, HBeAg -ve/anti-HBe +ve, HBV DNA +ve), and 13 (10.8%) had the surface gene mutations (HBsAg -ve, HBeAg -ve, IgG anti-HBc, and HBV DNA +ve). The remaining 89 (74.2%) patients were infected with wild type HBV. The course of all patients with mutant forms and 41 of those with the wild type form was followed for a mean (+/- SD) of 4.4 +/- 2.4 yr.
RESULTS: Compared with wild-type-infected patients, those with surface mutation were younger (39.9 +/- 14 vs. 30.1 +/- 12.4 yr, p < 0.05). Patients with precore mutations had a shorter illness than those with surface mutant (p < 0.01) and wild forms (p < 0.05). Histologically, patients with precore type had more active liver disease than wild type (39% vs. 15%, p < 0.05). Patients with precore mutations were always symptomatic, often presenting with ascites (67%) and jaundice (55%). Patients with surface mutant forms often presented with quiescent cirrhosis (77%) or cirrhosis with hepatoma (15%).
CONCLUSIONS: One-fourth of HBV-related chronic liver disease in Asian Indians is attributable to mutant HBV forms. The presence of variant viruses alters the natural history of the disease, with the precore variance having a more aggressive course and the surface mutant, a more quiescent but unfavorable course, compared with the wild type.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8677985

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  12 in total

1.  Analysis of point mutation in site 1896 of HBV precore and its detection in the tissues and serum of HCC patients.

Authors:  Yuan Wang; Hu Liu; Qing Zhou; Xu Li
Journal:  World J Gastroenterol       Date:  2000-06       Impact factor: 5.742

2.  Hepatitis B Virus Infection: Emerging Challenges for the Armed Forces.

Authors:  A C Anand; P Puri
Journal:  Med J Armed Forces India       Date:  2011-07-21

Review 3.  Risk factors for hepatocellular carcinoma in India.

Authors:  Premashis Kar
Journal:  J Clin Exp Hepatol       Date:  2014-04-13

4.  Hepatitis B Virus (HBV) Infection in Liver Disease Patients in Mumbai, India with Special Reference to Hepatitis B Surface Antigen (HBsAg) Mutant Detection.

Authors:  Shweta P Kamat; Preeti R Mehta; Supriya M Paranjpe; Nayana A Ingole
Journal:  J Clin Diagn Res       Date:  2014-03-15

Review 5.  Risk and management of blood-borne infections in health care workers.

Authors:  E M Beltrami; I T Williams; C N Shapiro; M E Chamberland
Journal:  Clin Microbiol Rev       Date:  2000-07       Impact factor: 26.132

6.  High frequency of the 1896 precore mutation in patients and blood donors with hepatitis B virus infection from the Indian subcontinent.

Authors:  Perumal Vivekanandan; Priya Abraham; Gopalan Sridharan; George Chandy; Ramachandran V Shaji; Dolly Daniel; Sukanya Raghuraman; Hubert Darius Daniel; Thenmozhi Subramaniam
Journal:  Mol Diagn       Date:  2004

7.  Clinical significance of genotypes and precore/basal core promoter mutations in HBV related chronic liver disease patients in North India.

Authors:  Sanjeev Sharma; Balkrishan Sharma; Bhupesh Singla; Yogesh Kumar Chawla; Anuradha Chakraborti; Nitin Saini; Ajay Duseja; Ashim Das; Radha Krishan Dhiman
Journal:  Dig Dis Sci       Date:  2009-12-31       Impact factor: 3.199

8.  Evolution of hepatitis B virus surface gene and protein among Iranian chronic carriers from different provinces.

Authors:  Fatemeh Ramezani; Seyed Moayed Alavian; Ahmadreza Sadeghi; Abolfazl Khedive; Leila Ghalichi; Mehdi Norouzi; Hadi Karimzadeh; Reza Malekzadeh; Ghodrat Montazeri; Azim Nejatizadeh; Masood Ziaee; Farshid Abedi; Behrooz Ataei; Majid Yaran; Babak Sayad; Mohamad Hosein Somi; Gholamreza Sarizadeh; Ismail Sanei-Moghaddam; Fariborz Mansour-Ghanaei; Houshang Rafatpanah; Hossein Keyvani; Ebrahim Kalantari; Mehdi Saberfiroozi; Reza Rezaee; Maryam Daram; Mostafa Mahabadi; Zahra Goodarzi; Vahdat Poortahmasebi; Babak Geravand; Azam Khamseh; Masoud Mahmoodi; Seyed Mohammad Jazayeri
Journal:  Iran J Microbiol       Date:  2015-08

Review 9.  Current Scenario of Hepatitis B and Its Treatment in India.

Authors:  Gautam Ray
Journal:  J Clin Transl Hepatol       Date:  2017-07-08

Review 10.  Large variations in risk of hepatocellular carcinoma and mortality in treatment naïve hepatitis B patients: systematic review with meta-analyses.

Authors:  Maja Thiele; Lise Lotte Gluud; Annette Dam Fialla; Emilie Kirstine Dahl; Aleksander Krag
Journal:  PLoS One       Date:  2014-09-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.